Amundi
INO icon

Amundi’s Inovio Pharmaceuticals INO Stock Holding History

Amundi’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,606
Closed -$118K – 1986
2024
Q1 		$118K Sell
11,606
-1
-0% -$9 ﹤0.01% 1739
2023
Q4 		$120K Buy
+11,607
New +$57.3K ﹤0.01% 1737
2023
Q2 		– Sell
-1,626
Closed -$13.6K – 2076
2023
Q1 		$13.6K Hold
1,626
– – ﹤0.01% 1992
2022
Q4 		$33.8K Hold
1,626
– – ﹤0.01% 1747
2022
Q3 		$35K Buy
+1,626
New +$41.6K ﹤0.01% 1709

Other funds holding INO

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Amundi's INO Position: Q2 2024 in Review

Amundi sold out of Inovio Pharmaceuticals (INO) in Q2 2024, closing a stake of 11,606 shares — an estimated $118K sold.

Amundi first reported a position in INO in Q3 2022 and held it in 5 quarters. The position peaked at $120K in Q4 2023. 96 funds tracked by Wall St. Rank hold INO as of Q2 2024.

  • Amundi reported no remaining Inovio Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Amundi sold 11,606 Inovio Pharmaceuticals shares in Q2 2024, an estimated $118K.
  • Amundi first reported a position in Inovio Pharmaceuticals in Q3 2022 and held it in 5 quarters.
  • Amundi's Inovio Pharmaceuticals position peaked at $120K in Q4 2023.
  • 96 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2024.

Based on Amundi's 13F filing for Q2 2024, filed 14 Aug 2024.